- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.09. | This week in charts: RA's insatiable appetite, Novartis' big slide and a reverse merger spree | ||
| 11.09. | Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use | ||
| 11.09. | mRNA cancer vaccines' biggest barriers to market | ||
| 10.09. | FDA places partial hold on Biohaven's epilepsy drug | ||
| 10.09. | Andy Plump, architect of Takeda's R&D overhaul, to retire next year | ||
| 10.09. | A booming business on Wall Street would love more biotechs to quietly die | ||
| 09.09. | Tyra disappoints investors with bladder cancer data | ||
| 09.09. | Kura spins diabetes work into a Lilly-backed biotech startup | ||
| 09.09. | FDA gains 'continuity' as Mikhail, Davis named permanent CBER, CDER leaders | ||
| 09.09. | A new immuno-oncology play raises $225M for a next-generation drug | ||
| 09.09. | Six AI agents, one deskside system: A new model for clinical decision support | ||
| 08.09. | Roivant surges on 'exceptional' results; Bristol Myers touts first-of-its-kind CAR-T therapy | ||
| 08.09. | Moonwalk reloads with $70M and new RNAi prospects for obesity | ||
| 08.09. | Novartis RNA drug falls short in rare muscle disease study | ||
| 08.09. | BrainChild hauls in $116M to make cell therapies for childhood brain cancers | ||
| 04.09. | Trailing rivals, AbbVie scores win with dual-acting myeloma drug | ||
| 04.09. | This week in charts: China deals, stock flatlines and Lilly's M&A spree | ||
| 04.09. | Ionis' rare neurology drug approved; Pfizer inks an ADC deal | ||
| 03.09. | An AI drug specialist zeroes in on rare forms of obesity | ||
| 03.09. | GSK wagers up to $1.3B on a different kind of cancer drug | ||
| 03.09. | Akeso, Summit cancer drug confirms lung cancer survival benefit | ||
| 03.09. | Ultragenyx to weigh 'significant' cost cuts as Angelman drug fails key study | ||
| 03.09. | The hidden scale-out problem behind CAR-T's growth | ||
| 02.09. | Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts | ||
| 02.09. | UniQure, after setbacks, seeks FDA approval of Huntington's gene therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.